Link between link between metabolic syndrome and insulin resistance

Current Vascular Pharmacology

Volumn 15, Issue 1, 2017, Pages 30-39

  Gluvic, Zoran ^a   Zaric, Bozidarka ^b   Resanovic, Ivana ^c   Obradovic, Milan ^c   Mitrovic, Aleksandar ^d   Radak, Djordje ^e   Isenovic, Esma R ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d CLINICAL CENTER OF SERBIA   (Serbia)

^e UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Cardiovascular disease; Insulin resistance; Metabolic syndrome

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; INSULIN;

ABDOMINAL OBESITY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC STRESS; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PHYSICAL ACTIVITY; REVIEW; WAIST CIRCUMFERENCE; ANIMAL; BLOOD; GLUCOSE BLOOD LEVEL; METABOLISM; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; HUMANS; INSULIN; INSULIN RESISTANCE; METABOLIC SYNDROME X; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 85018402316     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/1570161114666161007164510     Document Type: Review

References (158)

1. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol 2005; 4(4): 198-203.
2. Wilson PW, D’Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112(20): 3066-72.
3. Katsiki N, Athyros VG, Karagiannis A, et al. Should we expand the concept of coronary heart disease equivalents? Curr Opin Cardiol 2014; 29(4): 389-95.
4. Katsiki N, Athyros VG, Karagiannis A, et al. Metabolic syndrome and non-cardiac vascular diseases: an update from human studies. Curr Pharm Des 2014; 20(31): 4944-52.
5. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva, 1999.
6. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003; 108(13): 1546-51.
7. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640-5.
8. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164(10): 1066-76.
9. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93(2): 136-41.
10. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle- aged men. JAMA 2002; 288(21): 2709-16.
11. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110(10): 1245-50.
12. Haidara M, Mikhailidis DP, Yassin HZ, et al. Evaluation of the possible contribution of antioxidants administration in metabolic syndrome. Curr Pharm Des 2011; 17(33): 3699-712.
13. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome--a new worldwide definition. Lancet 2005; 366(9491): 1059-62.
14. Kylin E. Studien ueber das Hypertonie-Hyperglyca “mie-Hyperurika” miesyndrom. Zentralblatt fuer Innere Medizin 1923; 44: 105-27.
15. J. V. Sexual differentiation. A factor affecting the forms of obesity. Presse Medicale 1947; 30: S39-40.
16. Avogaro P, Crepaldi G. Essential hyperlipidemia, obesity and diabetes. Diabetologia 1965; 1: 137.
17. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993; 44: 121-31.
18. Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41(6): 715-22.
19. Hanefeld M, Leonhardt W. Das Metabolische Syndrom. Dt Gesundh Wesen 1981; 36: 545-51.
20. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. 1988. Nutrition 1997; 13(1): 65; discussion 64, 66.
21. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14(3): 173-94.
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15(7): 539-53.
23. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106(25): 3143-421.
24. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res 1998; 6 Suppl 2: 51S-209S.
25. Rabkin SW. The relationship between epicardial fat and indices of obesity and the metabolic syndrome: a systematic review and meta- analysis. Metab Syndr Relat Disord 2014; 12(1): 31-42.
26. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999; 16(5): 442-3.
27. Kaur J. A Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract 2014.
28. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world-a growing challenge. N Engl J Med 2007; 356(3): 213-5.
29. Desroches S, Lamarche B. The evolving definitions and increasing prevalence of the metabolic syndrome. Appl Physiol Nutr Metab 2007; 32(1): 23-32.
30. Kolovou GD, Anagnostopoulou KK, Salpea KD, et al. The prevalence of metabolic syndrome in various populations. Am J Med Sci 2007; 333(6): 362-71.
31. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004; 33(2): 351-75, table of contents.
32. Delva J, O’Malley PM, Johnston LD. Racial/ethnic and socioeconomic status differences in overweight and health-related behaviors among American students: national trends 1986-2003. J Adolesc Health 2006; 39(4): 536-45.
33. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163(4): 427-36.
34. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287(3): 356-9.
35. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53(8): 2087-94.
36. Athyros VG, Ganotakis ES, Tziomalos K, et al. Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin 2010; 26(3): 713-9.
37. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28(4): 629-36.
38. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
39. Federation ID. The IDF consensus worldwide definition of the metabolic syndrome. 2006. Available from: http://www.idf.org/metabolic-syndrome.
40. Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9(3): 237-52.
41. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17): 2735-52.
42. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis 2007; 17(4): 319-26.
43. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109(3): 433-8.
44. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: i-xii, 1-253.
45. Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res 2005; 46(11): 2347-55.
46. Lau DC, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005; 288(5): H2031-41.
47. Katsiki N, Athyros VG, Karagiannis A, et al. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol 2014; 12(4): 627-41.
48. Kirilmaz B, Asgun F, Alioglu E, et al. High inflammatory activity related to the number of metabolic syndrome components. J Clin Hypertens (Greenwich) 2010; 12(2): 136-44.
49. Goncalves FM, Jacob-Ferreira AL, Gomes VA, et al. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome. Clin Chim Acta 2009; 403(1-2): 173-7.
50. Boden G, Lebed B, Schatz M, et al. Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 2001; 50(7): 1612-7.
51. Kahn SE, Prigeon RL, Schwartz RS, et al. Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity. J Nutr 2001; 131(2): 354S-60S.
52. Liu M, Liu F. Transcriptional and post-translational regulation of adiponectin. Biochem J 2010; 425(1): 41-52.
53. Stokic E, Kupusinac A, Tomic-Naglic D, et al. Obesity and vitamin D deficiency: trends to promote a more proatherogenic cardiometabolic risk profile. Angiology 2015; 66(3): 237-43.
54. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92(3): 347-55.
55. Jacobs M, van Greevenbroek MM, van der Kallen CJ, et al. Lowgrade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009; 39(6): 437-44.
56. Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24(1): 29-33.
57. Kazumi T, Kawaguchi A, Sakai K, et al. Young men with highnormal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 2002; 25(6): 971-6.
58. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291(14): 1730-7.
59. Fumeron F, Aubert R, Siddiq A, et al. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes 2004; 53(4): 1150-7.
60. Xydakis AM, Case CC, Jones PH, et al. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab 2004; 89(6): 2697-703.
61. Soskic S, Stokic E, Obradovic M, et al. Association of leptin gene polymorphism G-2548A with metabolic and anthropometric parameters in obese patients in a Serbian population: pilot study. Clinical Lipidology 2014; 9: 505-13.
62. Carlyle M, Jones OB, Kuo JJ, et al. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 2002; 39(2 Pt 2): 496-501.
63. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334(5): 292-5.
64. Kypreos KE, Zafirovic S, Petropoulou PI, et al. Regulation of endothelial nitric oxide synthase and high-density lipoprotein quality by estradiol in cardiovascular pathology. J Cardiovasc Pharmacol Ther 2014; 19(3): 256-68.
65. Nikolic D, Katsiki N, Montalto G, et al. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013; 5(3): 928-48.
66. Mikhailidis DP, Elisaf M, Rizzo M, et al. European panel on low density lipoprotein (LDL) subclasses: A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 2011; 9(5): 531-2.
67. Mikhailidis DP, Elisaf M, Rizzo M, et al. “European panel on low density lipoprotein (LDL) subclasses”: A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9(5): 533-71.
68. Vague J. Sexual differentiation. A determinant factor of the forms of obesity. 1947. Obes Res 1996; 4(2): 201-3.
69. Valensi P, Avignon A, Sultan A, et al. Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: A cross-sectional study. Cardiovascular Diabetology 2016; 15: 104.
70. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998; 105(1A): 32S-39S.
71. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006; 291(3): H985-1002.
72. Popovic M, Smiljanic K, Dobutovic B, et al. Thrombin and vascular inflammation. Mol Cell Biochem 2012; 359(1-2): 301-13.
73. Davidovic L, Vodenicharov M, Affar EB, et al. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP- ribose) metabolism. Exp Cell Res 2001; 268(1): 7-13.
74. Taddei S, Caraccio N, Virdis A, et al. Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto’s thyroiditis. J Clin Endocrinol Metab 2006; 91(12): 5076-82.
75. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340(2): 115-26.
76. Resanovic I, Rizzo M, Zafirovic S, et al. Anti-atherogenic effects of 17beta-estradiol. Horm Metab Res 2013; 45(10): 701-8.
77. Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101(9): 948-54.
78. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101(16): 1899-906.
79. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol 1999; 34(3): 631-8.
80. Escobales N, Crespo MJ. Oxidative-nitrosative stress in hypertension. Curr Vasc Pharmacol 2005; 3(3): 231-46.
81. Linke A, Recchia F, Zhang X, et al. Acute and chronic endothelial dysfunction: implications for the development of heart failure. Heart Fail Rev 2003; 8(1): 87-97.
82. Wolin MS. Reactive oxygen species and vascular signal transduction mechanisms. Microcirculation 1996; 3(1): 1-17.
83. Pacher P, Szabo C. Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol 2006; 6(2): 136-41.
84. Ungvari Z, Gupte SA, Recchia FA, et al. Role of oxidativenitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol 2005; 3(3): 221-9.
85. Landmesser U, Drexler H. The clinical significance of endothelial dysfunction. Curr Opin Cardiol 2005; 20(6): 547-51.
86. Zago AS, Zanesco A. Nitric oxide, cardiovascular disease and physical exercise. Arq Bras Cardiol 2006; 87(6): e264-70.
87. Flammer AJ, Luscher TF. Three decades of endothelium research: from the detection of nitric oxide to the everyday implementation of endothelial function measurements in cardiovascular diseases. Swiss Med Wkly 2010; 140: w13122.
88. Napoli C, Ignarro LJ. Nitric oxide and pathogenic mechanisms involved in the development of vascular diseases. Arch Pharm Res 2009; 32(8): 1103-8.
89. Martin LJ, North KE, Dyer T, et al. Phenotypic, genetic, andgenome-wide structure in the metabolic syndrome. BMC Genet 2003; 4 Suppl 1: S95.
90. Poulsen P, Levin K, Petersen I, et al. Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes 2005; 54(1): 275-83.
91. Mendizabal Y, Llorens S, Nava E. Hypertension in metabolic syndrome: vascular pathophysiology. Int J Hypertens 2013; 2013: 230868.
92. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37(12): 1595-607.
93. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89(6): 2595-600.
94. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26(10): 2200-7.
95. Cigolini M, Targher G, Bergamo Andreis IA, et al. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16(3): 368-74.
96. Alessi MC, Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mal Coeur Vaiss 2004; 97(6): 673-8.
97. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342(24): 1792-801.
98. Trpkovic A, Stanimirovic J, Rizzo M, et al. High-sensitivity C-reactive protein and statin initiation. Angiology 2015; 66(6): 503-7.
99. Fasshauer M, Kralisch S, Klier M, et al. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2003; 301(4): 1045-50.
100. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286(3): 327-34.
101. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27(6): 1496-504.
102. Hotamisligil GS, Peraldi P, Budavari A, et al. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 1996; 271(5249): 665-8.
103. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107(3): 391-7.
104. Clearfield MB. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 2005; 105(9): 409-16.
105. Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol 2005; 67: 259-84.
106. Wang CN, McLeod RS, Yao Z, et al. Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes. Arterioscler Thromb Vasc Biol 1995; 15(9): 1481-91.
107. Argaud D, Zhang Q, Pan W, et al. Regulation of rat liver glucose- 6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5’-flanking sequence. Diabetes 1996; 45(11): 1563-71.
108. Hauner H, Entenmann G, Wabitsch M, et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 1989; 84(5): 1663-70.
109. Guillaume-Gentil C, Assimacopoulos-Jeannet F,Jeanrenaud B. Involvement of non-esterified fatty acid oxidation in glucocorticoid-induced peripheral insulin resistance in vivo in rats. Diabetologia 1993; 36(10): 899-906.
110. Chrousos GP. Stress and disorders of the stress system. Nat Rev Endocrinol 2009; 5(7): 374-81.
111. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149(7): 1514-20.
112. Azad SS, Isenovic ER, Yaturu S, et al. in Type 2 Diabetes: Insulin Therapy for Diabetes; Masuo K, Editor. In Tech 2013.
113. Gill H, Mugo M, Whaley-Connell A, et al. The key role of insulin resistance in the cardiometabolic syndrome. Am J Med Sci 2005; 330(6): 290-4.
114. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med 2006; 119(5 Suppl 1): S10-6.
115. Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113(15): 1888-904.
116. Jensen MD, Haymond MW, Rizza RA, et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 1989; 83(4): 1168-73.
117. Jagroop IA, Daskalopoulou SS, Mikhailidis DP. Endothelin-1 and human platelets. Curr Vasc Pharmacol 2005; 3(4): 393-9.
118. Lusis AJ. Atherosclerosis. Nature 2000; 407(6801): 233-41.
119. Trpkovic A, Resanovic I, Stanimirovic J, et al. Oxidized lowdensity lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci 2015; 52(2): 70-85.
120. Katsiki N, Athyros VG, Mikhailidis DP. Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk? Curr Vasc Pharmacol 2016.
121. Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21(22): 6820-34.
122. Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65(8): 1109-23.
123. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 2014; 37(10): 2843-63.
124. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 2005; 13(6): 322-7.
125. Rizzo M, Rizvi AA, Rini GB, et al. The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance? Acta Diabetol 2009; 46(1): 1-11.
126. Abbasi F, McLaughlin T, Lamendola C, et al. High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk. Am J Cardiol 2000; 85(1): 45-8.
127. Dallak MM, Mikhailidis DP, Haidara MA, et al. Oxidative stress as a common mediator for apoptosis induced-cardiac damage in diabetic rats. Open Cardiovasc Med J 2008; 2: 70-8.
128. Ferdinandy P, Schulz R. Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2003; 138(4): 532-43.
129. Katsiki N, Manes C. Is there a role for supplemented antioxidants in the prevention of atherosclerosis? Clin Nutr 2009; 28(1): 3-9.
130. Grattagliano I, Caraceni P, Calamita G, et al. Severe liver steatosis correlates with nitrosative and oxidative stress in rats. Eur J Clin Invest 2008; 38(7): 523-30.
131. Moreau KL, Gavin KM, Plum AE, et al. Ascorbic acid selectively improves large elastic artery compliance in postmenopausal women. Hypertension 2005; 45(6): 1107-12.
132. Farvid MS, Jalali M, Siassi F, et al. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 2005; 28(10): 2458-64.
133. Haidara MA, Yassin HZ, Zakula Z, et al. Diabetes and antioxidants: myth or reality? Curr Vasc Pharmacol 2010; 8(5): 661-72.
134. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136(6): 734-8.
135. Sautin YY, Nakagawa T, Zharikov S, et al. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidasemediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293(2): C584-96.
136. Yuan H, Yu C, Li X, et al. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies. J Clin Endocrinol Metab 2015; 100(11): 4198-207.
137. Katsiki N, Karagiannis A, Athyros VG, et al. Hyperuricaemia: more than just a cause of gout? J Cardiovasc Med (Hagerstown) 2013; 14(6): 397-402.
138. Katsiki N, Papanas N, Fonseca VA, et al. Uric acid and diabetes: Is there a link? Curr Pharm Des 2013; 19(27): 4930-7.
139. Johnson RJ. Why focus on uric acid? Curr Med Res Opin 2015; 31 Suppl 2 3-7.
140. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14(3): 137-45.
141. Ishibashi M, Egashira K, Hiasa K, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002; 40(5): 687-93.
142. Staels B. PPAR agonists and the metabolic syndrome. Therapie 2007; 62(4): 319-26.
143. Kinjo K, Sato H, Sakata Y, et al. Relation of C-reactive protein and one-year survival after acute myocardial infarction with versus without statin therapy. Am J Cardiol 2005; 96(5): 617-21.
144. Katsiki N, Athyros VG, Karagiannis A, et al. The role of statins in the treatment of type 2 diabetes mellitus: an update. Curr Pharm Des 2014; 20(22): 3665-74.
145. Paraskevas KI, Stathopoulos V,Mikhailidis DP. Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol 2008; 6(4): 237-9.
146. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004; 20(5): 627-37.
147. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357(13): 1301-10.
148. Maki KC. Fibrates for treatment of the metabolic syndrome. Curr Atheroscler Rep 2004; 6(1): 45-51.
149. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563-74.
150. Katsiki N, Nikolic D, Montalto G, et al. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des 2013; 19(17): 3124-31.
151. Katsiki N, Theocharidou E, Karagiannis A, et al. Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des 2013; 19(17): 3107-14.
152. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27(1): 155-61.
153. Durbin RJ. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 2004; 6(4): 280-5.
154. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51(9): 2796-803.
155. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23(11): 1605-11.
156. Inzucchi SE, Furie KL. The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone. J Diabetes 2016; 8(5): 607-9.
157. Rojas LB, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 2013; 5(1): 6.
158. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346(6): 393-403.